Prosecution Insights
Last updated: October 25, 2026
Application No. 18/931,464

Formulations of Enzalutamide

Non-Final OA §102
Filed
Oct 30, 2024
Priority
Sep 11, 2012 — provisional 61/699,351 +11 more
Examiner
AZPURU, CARLOS A
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Medivation Prostate Therapeutics LLC
OA Round
1 (Non-Final)
84%
Grant Probability
Favorable
1-2
OA Rounds
8m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1092 granted / 1303 resolved
+23.8% vs TC avg
Moderate +11% lift
Without
With
+10.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
37 currently pending
Career history
1330
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
24.4%
-15.6% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
30.5%
-9.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1303 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. A Preliminary amendment was filed on 01/14/2025. Terminal Disclaimer A terminal disclaimer over US Patent No. 11,839,689 was approved on 11/07/2024. A Track One Request was denied on 12/03/2024 Information Disclosure Statement Information disclosure statements were filed on 02/31/2025, 03/05/2025, 03/19/2025, 05/12/2025, 06/03/2025, 06/19/2025, 06/24/2025, 07/16/2025, 08202025. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – Claim(s) 1-2 is/are rejected under pre-AIA 35 U.S.C. 102(a)(2) as being anticipated by WO 2014/043208 (WO’208) WO’208 discloses a solid dispersion of amorphous dispersion of amorphous enzalutamide in a cellulosic concentration enhancing polymer such as HPMCAS See process described on page 9; and claim 11, step a). The patent also comprises ionizable non-cellulosic polymers at [55]- [56] which are copolymers of methacrylate and acrylate. He claims are anticipated by WO’208. Conclusion No claims are allowed. The declaration under 37 CFR 1.131(a) filed 10/13/2024 is noted. However, it is directed to derivation of an amorphous enzalutamide dispersion comprising HPMCAS which is not claimed in the instant application, and is therefore ineffective over the reference cited above. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to CARLOS A AZPURU whose telephone number is (571)272-0588. The examiner can normally be reached 9 am- 3 pm, 4 pm-8pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue X Liu can be reached at 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CARLOS A AZPURU/Primary Examiner, Art Unit 1617 caz
Read full office action

Prosecution Timeline

Oct 30, 2024
Application Filed
Jan 14, 2025
Response after Non-Final Action
Sep 29, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758507
METHOD FOR PREPARING DRUG-LOADED SILK FIBROIN NANOCAPSULE, AND PRODUCT THEREOF
4y 9m to grant Granted Oct 13, 2026
Patent 12758531
PHARMACEUTICAL COMPOSITIONS COMPRISING IONIC LIQUIDS
3y 8m to grant Granted Oct 13, 2026
Patent 12757895
RE-OILED AND HYPER-OILED LECITHIN CARRIER VEHICLES
3y 6m to grant Granted Oct 13, 2026
Patent 12758684
IMPLANT FOR OVARIAN DECLINE AND METHODS OF MANUFACTURING AN IMPLANT FOR OVARIAN DECLINE
3y 2m to grant Granted Oct 13, 2026
Patent 12758499
PLASMA COATING METHOD OF NANOVESICLE SURFACE AND PLASMA JET DEVICE FOR PLASMA COATING OF NANOVESICLE SURFACE
2y 3m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
84%
Grant Probability
95%
With Interview (+10.8%)
2y 7m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1303 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month